Ritechem Pharmacy Limited - Period Ending 2020-07-31

Ritechem Pharmacy Limited - Period Ending 2020-07-31


Ritechem Pharmacy Limited 00639801 false 2019-08-01 2020-07-31 2020-07-31 The principal activity of the company is that of running a pharmacy. Digita Accounts Production Advanced 6.29.9459.0 true 00639801 2019-08-01 2020-07-31 00639801 2020-07-31 00639801 core:CurrentFinancialInstruments 2020-07-31 00639801 core:CurrentFinancialInstruments core:WithinOneYear 2020-07-31 00639801 core:Non-currentFinancialInstruments core:AfterOneYear 2020-07-31 00639801 core:Goodwill 2020-07-31 00639801 core:FurnitureFittings 2020-07-31 00639801 core:LandBuildings core:OwnedOrFreeholdAssets 2020-07-31 00639801 core:OfficeEquipment 2020-07-31 00639801 bus:SmallEntities 2019-08-01 2020-07-31 00639801 bus:AuditExemptWithAccountantsReport 2019-08-01 2020-07-31 00639801 bus:FullAccounts 2019-08-01 2020-07-31 00639801 bus:SmallCompaniesRegimeForAccounts 2019-08-01 2020-07-31 00639801 bus:RegisteredOffice 2019-08-01 2020-07-31 00639801 bus:Director1 2019-08-01 2020-07-31 00639801 bus:PrivateLimitedCompanyLtd 2019-08-01 2020-07-31 00639801 core:Goodwill 2019-08-01 2020-07-31 00639801 core:Buildings 2019-08-01 2020-07-31 00639801 core:FurnitureFittings 2019-08-01 2020-07-31 00639801 core:Land 2019-08-01 2020-07-31 00639801 core:LandBuildings core:OwnedOrFreeholdAssets 2019-08-01 2020-07-31 00639801 core:OfficeEquipment 2019-08-01 2020-07-31 00639801 countries:AllCountries 2019-08-01 2020-07-31 00639801 2019-07-31 00639801 core:Goodwill 2019-07-31 00639801 core:FurnitureFittings 2019-07-31 00639801 core:LandBuildings core:OwnedOrFreeholdAssets 2019-07-31 00639801 core:OfficeEquipment 2019-07-31 00639801 2018-08-01 2019-07-31 00639801 2019-07-31 00639801 core:CurrentFinancialInstruments 2019-07-31 00639801 core:CurrentFinancialInstruments core:WithinOneYear 2019-07-31 00639801 core:Non-currentFinancialInstruments core:AfterOneYear 2019-07-31 00639801 core:Goodwill 2019-07-31 00639801 core:FurnitureFittings 2019-07-31 00639801 core:LandBuildings core:OwnedOrFreeholdAssets 2019-07-31 00639801 core:OfficeEquipment 2019-07-31 iso4217:GBP xbrli:pure

Registration number: 00639801

Ritechem Pharmacy Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 July 2020

 

Ritechem Pharmacy Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Ritechem Pharmacy Limited

Company Information

Director

Mr S Hedayati

Registered office

277-279 Chiswick High Road
Chiswick
London
W4 4PU

Accountants

Flintham Mackenzie Ltd
Chartered Accountants
277 - 279 Chiswick High Road
London
W4 4PU

 

Ritechem Pharmacy Limited

(Registration number: 00639801)
Balance Sheet as at 31 July 2020

Note

2020
£

2019
£

Fixed assets

 

Intangible assets

4

-

1

Tangible assets

5

34,827

42,989

Investments

6

212,787

177,487

 

247,614

220,477

Current assets

 

Stocks

7

125,152

127,350

Debtors

8

154,901

225,580

Cash at bank and in hand

 

99,574

13,034

 

379,627

365,964

Creditors: Amounts falling due within one year

9

(242,793)

(258,904)

Net current assets

 

136,834

107,060

Total assets less current liabilities

 

384,448

327,537

Creditors: Amounts falling due after more than one year

9

(50,000)

-

Provisions for liabilities

(5,125)

(5,948)

Net assets

 

329,323

321,589

Capital and reserves

 

Called up share capital

25,371

25,371

Capital redemption reserve

6,481

6,481

Profit and loss account

297,471

289,737

Shareholders' funds

 

329,323

321,589

For the financial year ending 31 July 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

 

Ritechem Pharmacy Limited

(Registration number: 00639801)
Balance Sheet as at 31 July 2020

Approved and authorised by the director on 3 June 2021
 

.........................................

Mr S Hedayati
Director

 

Ritechem Pharmacy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2020

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
277-279 Chiswick High Road
Chiswick
London
W4 4PU

These financial statements were authorised for issue by the director on 3 June 2021.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Ritechem Pharmacy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2020

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Land

Nil

Buildings

Reducing balance at 15%

Furniture and fittings

Reducing balance at 15%

Office equipment

Reducing balance at 33%

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Reducing balance at 5%

 

Ritechem Pharmacy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2020

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

 

Ritechem Pharmacy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2020

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 4 (2019 - 4).

 

Ritechem Pharmacy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2020

4

Intangible assets

Goodwill
 £

Total
£

Cost or valuation

At 1 August 2019

121,345

121,345

At 31 July 2020

121,345

121,345

Amortisation

At 1 August 2019

121,344

121,344

Amortisation charge

1

1

At 31 July 2020

121,345

121,345

Carrying amount

At 31 July 2020

-

-

At 31 July 2019

1

1

5

Tangible assets

Land and buildings
£

Fixtures and fittings
£

Office equipment
£

Total
£

Cost or valuation

At 1 August 2019

39,088

230,988

67,269

337,345

At 31 July 2020

39,088

230,988

67,269

337,345

Depreciation

At 1 August 2019

33,283

202,313

58,760

294,356

Charge for the year

1,024

4,302

2,836

8,162

At 31 July 2020

34,307

206,615

61,596

302,518

Carrying amount

At 31 July 2020

4,781

24,373

5,673

34,827

At 31 July 2019

5,805

28,675

8,509

42,989

Included within the net book value of land and buildings above is £4,781 (2019 - £5,805) in respect of freehold land and buildings.
 

6

Investments

2020
£

2019
£

Fixed asset group loan

212,787

177,487

 

Ritechem Pharmacy Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2020

Fixed asset group loan

£

Cost or valuation

At 1 August 2019

177,487

Additions

35,300

At 31 July 2020

212,787

7

Stocks

2020
£

2019
£

Other inventories

125,152

127,350

8

Debtors

2020
£

2019
£

Trade debtors

89,000

118,218

Prepayments

14,516

83,278

Other debtors

51,385

24,084

154,901

225,580

9

Creditors

Creditors: amounts falling due within one year

2020
£

2019
£

Due within one year

Trade creditors

99,959

125,362

Taxation and social security

16,564

14,601

Accruals and deferred income

2,300

2,300

Other creditors

123,970

116,641

242,793

258,904

Creditors: amounts falling due after more than one year

Note

2020
£

2019
£

Due after one year

 

Loans and borrowings

50,000

-